Leading Alzheimer’s disease researchers and a prominent patient advocate today published an analysis, “Single Endpoint for New Drug Approvals for Alzheimer’s Disease,” urging the Food and Drug Administration (FDA) to clarify and modernize its current approach for approving new treatments for Alzheimer’s disease. The analysis, authored by George Vradenburg, UsAgainstAlzheimer’s Co-Founder and Chairman, and Drs.…